Investor Presentaiton

KRAZATI (adagrasib) Opportunity to expand to 1L NSCLC 1L NSCLC with TPS ≥ 50% Demonstrated early efficacy in combination with pembrolizumab • 63% ORR 1,2,3 (N=56) Substantially exceeds standard of care historical benchmark of 39%-45%4,5 Combination is well tolerated with low rates of clinically meaningful liver TRAES Initiating Phase 3 in this population Next Key Event Enrollment in Phase 3 adagrasib+/- pembrolizumab study expected before YE 2023 1L NSCLC with TPS < 50% Strategy to raise the standard of care through combination with chemotherapy and pembrolizumab adagrasib + chemo-pembro combination Phase 2 study underway (KRYSTAL-17) Next Key Event Data expected for KRYSTAL-17 adagrasib + chemo- immunotherapy study in 1H 2024 1. One confirmed response confirmed subsequent to data cut off; full analysis set includes 3 protocol violations (n=56); 2. Excluding 3 protocol violations, ORR was 66% (n=53); 3. Among clinical activity evaluable (CAE) patients, defined as receiving at least one dose of adagrasib (400 mg BID) + pembrolizumab, having measurable disease at baseline, and having at least one post-baseline tumor assessment, the ORR was 71% (n=49); 4. ORR of 39% from KEYNOTE-42 and ORR of 45% from KEYNOTE- 24; 5. For illustrative purposes only: no head-to-head clinical trial has been conducted. Ill Bristol Myers Squibb™ Not for Product Promotional Use 10

View entire presentation